Form 4: Ginkgo Bioworks CFO Mark Dmytruk Executes Stock Transactions

Ginkgo Bioworks CFO Mark Dmytruk engaged in multiple transactions involving the company's stock, including the vesting of restricted stock units and a sale to cover tax obligations.

Summary

• Mark Dmytruk, the Chief Financial Officer of Ginkgo Bioworks Holdings, Inc., executed several transactions involving the company's Class A and Class B common stock.
• These transactions included the vesting of restricted stock units (RSUs) which converted into Class A common stock.
• A total of 1,517 RSUs vested and converted to Class A common stock on December 3, 2024.
• Additionally, 8 shares of Class B common stock were converted to Class A common stock on the same day.
• Dmytruk sold 741 shares of Class A common stock at a price of $9.644 per share on December 4, 2024, to cover tax withholding obligations related to the vesting of restricted stock and/or restricted stock units.
• Following these transactions, Dmytruk directly owns 32,386 shares of Class A common stock.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions related to equity compensation. While the sale of shares could be seen as slightly negative, it is a standard practice for tax purposes. Overall, the sentiment is neutral to slightly positive.

Positives

• The vesting of restricted stock units indicates that Dmytruk is meeting the conditions of his compensation package.
• The conversion of Class B shares to Class A shares is a standard process and does not indicate any negative sentiment.

Negatives

• The sale of 741 shares, while for tax purposes, could be interpreted as a slight negative signal, although it is a common practice.

Risks

• While the sale of shares was to cover tax obligations, large sales by insiders can sometimes be perceived negatively by the market.
• The vesting schedule of the RSUs could lead to further sales in the future to cover tax obligations.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Management Comments

• The document includes a statement that sales to cover tax withholding obligations do not represent discretionary trades by the Reporting Person.
• The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a 'sell to cover' transaction.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders engage in stock transactions. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent sale to cover taxes is a common practice among publicly traded companies, particularly in the technology and biotech sectors.
• Many companies, such as Moderna and BioNTech, use similar equity compensation structures for their executives.
• The 'sell to cover' mechanism is a standard method to manage tax obligations related to equity compensation, and is widely used across the industry.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are related to insider compensation and tax obligations.
• The sale of shares could slightly increase the supply of shares in the market, but the impact is likely to be minimal.

Key Dates

Keywords

Ginkgo Bioworks, stock transactions, Form 4, insider trading, restricted stock units, Class A common stock, Class B common stock, Mark Dmytruk, CFO, vesting